Abbott begins Voyager trial of its Encantor TAVI system and Leerink upgrades the stock
Abbott (ABT) began the Voyager trial to evaluate its Encantor TAVI system, software-guided and investigational, for aortic stenosis, and a pivotal U.S. trial is expected to start in the coming months. In addition, Leerink Partners upgraded Abbott from market perform to outperform and set a $124 price target, 18.7% above its November 18 close of $104.48.
In 30 seconds
- Abbott began the Voyager trial to evaluate its Encantor TAVI system, software-guided and investigational, for aortic stenosis.
- A pivotal U.S. trial is expected to start in the coming months.
- Leerink Partners upgraded Abbott from market perform to outperform.
IASummary generated by artificial intelligence from a story by TradingView. It may contain errors: the original source prevails.




Comments
Be respectful. Comments reported by several people are hidden until a moderator reviews them.
You do not need an account to read, only to comment. Sign in with a code sent to your email or with your Google account. We only show the name you choose, never your email.